• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CHRISTOPH MIETHKE GMBH & CO KG GAV 2.0 WITH DIST.CATHETER 10/30; HYDROCEPHALUS MANAGEMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CHRISTOPH MIETHKE GMBH & CO KG GAV 2.0 WITH DIST.CATHETER 10/30; HYDROCEPHALUS MANAGEMENT Back to Search Results
Model Number FX221T
Medical Device Problem Code Infusion or Flow Problem (2964)
Health Effect - Clinical Code Hydrocephalus (3272)
Date of Event 04/22/2024
Type of Reportable Event Serious Injury
Event or Problem Description
It was reported that a gav 2.0 (#fx221t) was implanted during a procedure performed on (b)(6) 2022.According to the complainant, the valve showed an under-drainage.The patient underwent a revision procedure performed on (b)(6) 2024.The complainant device has returned to the manufacturer for evaluation.No patient complications were reported as a result of the revision procedure.Age: 2 years, 4 months.Weight: 10 kgs.Height: 81 cm.Gender: female.
 
Additional Manufacturer Narrative
Visual inspection: during the investigation, no significant deformations or damage of the valves were determined.Permeability test: a permeability test has shown that the gav 2.0 is permeable.Computer controlled test: to investigate the claim of under-drainage, the opening pressure is measured using a miethke computer controlled testing apparatus which simulates a cerebrospinal fluid flow.The valve is tested in both the horizontal as well as the vertical positions.The results show that the valve does not operate within the accepted tolerance in either position.An accelerated outflow of gav 2.0 could be determined.Internal inspection: after dismantling of the valve, deposits were found inside.Results: based on our investigation results, we can determine an accelerated outflow in the valve in both positions.The determined deposits can be named as the cause for the accelerated outflow.Organic material in the cerebrospinal fluid can influence the function temporarily and are known side effects in hydrocephalus therapy.We can exclude a defect at the time of release.The valve met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required from our point of view.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GAV 2.0 WITH DIST.CATHETER 10/30
Common Device Name
HYDROCEPHALUS MANAGEMENT
Manufacturer (Section D)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM  14469
Manufacturer (Section G)
CHRISTOPH MIETHKE GMBH & CO KG
ulanenweg 2
potsdam, 14469
GM   14469
Manufacturer Contact
joerg knebel
ulanenweg 2
potsdam, 14469
GM   14469
MDR Report Key19226249
Report Number3004721439-2024-00122
Device Sequence Number15368158
Product Code JXG
UDI-Device Identifier04041906503239
UDI-Public4041906503239
Combination Product (Y/N)N
Initial Reporter CountryGM
PMA/510(K) Number
K190174
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2022
Device Explanted Year2024
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Foreign,User Facility,Company Representative
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date (Section B) 05/01/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Expiration Date03/31/2025
Device Model NumberFX221T
Device Catalogue NumberFX221T
Device Lot Number20047072
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer04/25/2024
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 04/25/2024
Initial Report FDA Received Date05/01/2024
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured03/31/2022
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age28 MO
Patient SexFemale
Patient Weight10 KG
-
-